The overall goal is the development of a medicament for the prevention and therapy of bacterial-induced Kolitiden and bowel disease of the forms circle of IBD (inflammatory bowel disease). Currently edited a 6monatiges project, which deals with the biological effectiveness, shelf life of serving as a Biocatalyst E.coli tribe, as well as issues the authorisation of E.coli as medicinal products and the efficiency of the overall project. The project is edited in a network of 12 partners from the Switzerland and Germany. Swiss partners include 2 national competence networks.
